| Messalina Charisse Jordan, DO | |
|
3520 Us Highway 431 Ste 100, Albertville, AL 35950-0082 | |
| (256) 849-0500 | |
| (256) 573-1021 |
| Full Name | Messalina Charisse Jordan |
|---|---|
| Gender | Female |
| Speciality | General Practice |
| Experience | 13 Years |
| Location | 3520 Us Highway 431 Ste 100, Albertville, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114218039 | NPI | - | NPPES |
| DO1305 | Other | AL | ALBME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | DO1305 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice Of Marshall County/shepherd's Cove | Albertville, AL | Hospice |
| Marshall Medical Centers | Boaz, AL | Hospital |
| Entity Name | American Family Care, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669429080 PECOS PAC ID: 9739087818 Enrollment ID: O20031229000157 |
News Archive
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.
Proteins, which form much of the molecular machinery required for life, are the targets of most drug molecules.
The nation's largest experiment in delivering medical care in an innovative way has reduced costs and improved the quality of care even more in its second year than in its first, according to the insurance company behind it.
Neurocrine Biosciences, Inc. has announced that they have resubmitted its New Drug Application (NDA) for indiplon 5 mg and 10 mg capsules for the treatment of insomnia in both adult and elderly patients to the U.S. Food and Drug Administration (FDA).
› Verified 7 days ago
| Entity Name | Capstone Health Services Foundation Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740397751 PECOS PAC ID: 6103724489 Enrollment ID: O20040330001160 |
News Archive
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.
Proteins, which form much of the molecular machinery required for life, are the targets of most drug molecules.
The nation's largest experiment in delivering medical care in an innovative way has reduced costs and improved the quality of care even more in its second year than in its first, according to the insurance company behind it.
Neurocrine Biosciences, Inc. has announced that they have resubmitted its New Drug Application (NDA) for indiplon 5 mg and 10 mg capsules for the treatment of insomnia in both adult and elderly patients to the U.S. Food and Drug Administration (FDA).
› Verified 7 days ago
| Entity Name | Correct Care, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215987441 PECOS PAC ID: 8628980992 Enrollment ID: O20040615000906 |
News Archive
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.
Proteins, which form much of the molecular machinery required for life, are the targets of most drug molecules.
The nation's largest experiment in delivering medical care in an innovative way has reduced costs and improved the quality of care even more in its second year than in its first, according to the insurance company behind it.
Neurocrine Biosciences, Inc. has announced that they have resubmitted its New Drug Application (NDA) for indiplon 5 mg and 10 mg capsules for the treatment of insomnia in both adult and elderly patients to the U.S. Food and Drug Administration (FDA).
› Verified 7 days ago
| Entity Name | Hospital Medicine Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093758781 PECOS PAC ID: 9234156985 Enrollment ID: O20061002000335 |
News Archive
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.
Proteins, which form much of the molecular machinery required for life, are the targets of most drug molecules.
The nation's largest experiment in delivering medical care in an innovative way has reduced costs and improved the quality of care even more in its second year than in its first, according to the insurance company behind it.
Neurocrine Biosciences, Inc. has announced that they have resubmitted its New Drug Application (NDA) for indiplon 5 mg and 10 mg capsules for the treatment of insomnia in both adult and elderly patients to the U.S. Food and Drug Administration (FDA).
› Verified 7 days ago
| Entity Name | App Of Alabama Ed Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659646040 PECOS PAC ID: 3577725068 Enrollment ID: O20120430000174 |
News Archive
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.
Proteins, which form much of the molecular machinery required for life, are the targets of most drug molecules.
The nation's largest experiment in delivering medical care in an innovative way has reduced costs and improved the quality of care even more in its second year than in its first, according to the insurance company behind it.
Neurocrine Biosciences, Inc. has announced that they have resubmitted its New Drug Application (NDA) for indiplon 5 mg and 10 mg capsules for the treatment of insomnia in both adult and elderly patients to the U.S. Food and Drug Administration (FDA).
› Verified 7 days ago
| Entity Name | Cahaba Medical Care Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316201809 PECOS PAC ID: 1355597923 Enrollment ID: O20121120000238 |
News Archive
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.
Proteins, which form much of the molecular machinery required for life, are the targets of most drug molecules.
The nation's largest experiment in delivering medical care in an innovative way has reduced costs and improved the quality of care even more in its second year than in its first, according to the insurance company behind it.
Neurocrine Biosciences, Inc. has announced that they have resubmitted its New Drug Application (NDA) for indiplon 5 mg and 10 mg capsules for the treatment of insomnia in both adult and elderly patients to the U.S. Food and Drug Administration (FDA).
› Verified 7 days ago
| Entity Name | Careplus Family Medical Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639503055 PECOS PAC ID: 9335374255 Enrollment ID: O20131031001169 |
News Archive
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.
Proteins, which form much of the molecular machinery required for life, are the targets of most drug molecules.
The nation's largest experiment in delivering medical care in an innovative way has reduced costs and improved the quality of care even more in its second year than in its first, according to the insurance company behind it.
Neurocrine Biosciences, Inc. has announced that they have resubmitted its New Drug Application (NDA) for indiplon 5 mg and 10 mg capsules for the treatment of insomnia in both adult and elderly patients to the U.S. Food and Drug Administration (FDA).
› Verified 7 days ago
| Entity Name | Childrens Urgent Care, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124541438 PECOS PAC ID: 9234405408 Enrollment ID: O20171017000804 |
News Archive
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.
Proteins, which form much of the molecular machinery required for life, are the targets of most drug molecules.
The nation's largest experiment in delivering medical care in an innovative way has reduced costs and improved the quality of care even more in its second year than in its first, according to the insurance company behind it.
Neurocrine Biosciences, Inc. has announced that they have resubmitted its New Drug Application (NDA) for indiplon 5 mg and 10 mg capsules for the treatment of insomnia in both adult and elderly patients to the U.S. Food and Drug Administration (FDA).
› Verified 7 days ago
| Entity Name | Boaz And Albertville Family Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245827203 PECOS PAC ID: 7113329343 Enrollment ID: O20210712001106 |
News Archive
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.
Proteins, which form much of the molecular machinery required for life, are the targets of most drug molecules.
The nation's largest experiment in delivering medical care in an innovative way has reduced costs and improved the quality of care even more in its second year than in its first, according to the insurance company behind it.
Neurocrine Biosciences, Inc. has announced that they have resubmitted its New Drug Application (NDA) for indiplon 5 mg and 10 mg capsules for the treatment of insomnia in both adult and elderly patients to the U.S. Food and Drug Administration (FDA).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Messalina Charisse Jordan, DO Po Box 22, Boaz, AL 35957-0022 Ph: (256) 849-0500 | Messalina Charisse Jordan, DO 3520 Us Highway 431 Ste 100, Albertville, AL 35950-0082 Ph: (256) 849-0500 |
News Archive
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.
Proteins, which form much of the molecular machinery required for life, are the targets of most drug molecules.
The nation's largest experiment in delivering medical care in an innovative way has reduced costs and improved the quality of care even more in its second year than in its first, according to the insurance company behind it.
Neurocrine Biosciences, Inc. has announced that they have resubmitted its New Drug Application (NDA) for indiplon 5 mg and 10 mg capsules for the treatment of insomnia in both adult and elderly patients to the U.S. Food and Drug Administration (FDA).
› Verified 7 days ago
Stephen J Babbino, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 604 Smith Rd, Albertville, AL 35951 Phone: 256-891-1460 Fax: 256-891-2640 | |
Larry R Johnston, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3442 Us Highway 431, Albertville, AL 35950 Phone: 256-593-1234 Fax: 256-593-8553 | |
Dr. Gary Alan Calhoun, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11491 Us Highway 431, Albertville, AL 35950 Phone: 256-894-6976 | |
Benjamin Favis, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8914 Us Highway 431, Careplus Family Medical, Albertville, AL 35950 Phone: 256-279-7200 Fax: 256-279-5757 | |
Dr. Morgan Lacey Goss, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 431 N Carlisle St, Albertville, AL 35950 Phone: 256-251-2566 Fax: 256-344-8334 | |
Dr. Michael Wayne Peters, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5104 Us Highway 431, Albertville, AL 35950 Phone: 256-878-8180 Fax: 256-891-3693 |